10 March 2021
Molecular Partners and Novartis announced positive initial results from an ongoing Phase I study of ensovibep, the former’s first tri-specific Covid-19 antiviral treatment, among healthy individuals. Initial findings show the drug was safe and effective; a Phase II/III registrational study is being planned for the second quarter of 2021.
Go deeper with GlobalData
US pharmacy Walgreens has administered approximately five million Covid-19 vaccinations across its stores, long-term care facilities, and through dedicated clinics. The company is supporting vaccination efforts across 43 US states and jurisdictions as part of the Federal Retail Pharmacy Program.
Sorrento Therapeutics announced major progress in developing COVISHIELD antibody combinations through a license agreement with researchers at the Icahn School of Medicine at Mount Sinai. The agreement allows for the collection of antibodies which have the SARS-CoV-2 virus neutralising properties developed by Mount Sinai. This follows on from the success of Sorrento’s intravenous STI-2020 (COVI-AMG) and its intranasal STI-2099 (COVIDROPS).
